Hepatitis C in patients co-infected with human immunodeficiency virus. A review and experience of a Brazilian ambulatory.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share the same transmission mechanisms. The prevalence of HCV in the HIV-infected population varies from region to region, throughout the world, depending on different exposure factors to both viruses. Co-infection with HIV accelerates the progression of the disease caused by HCV, appears to worsen the progression of the HIV infection and increases HCV transmission. Therefore, clinical management and treatment of HCV is a priority in medical facilities that receive HIV-infected patients. Clinical management of these patients involves specific diagnostic procedures and appropriately trained medical staff. The indication of treatment should meet specific clinical and laboratory criteria. There are a number of drugs currently available to treat hepatitis C in co-infected patients.
Mendes-Corrêa
Maria Cássia Jacintho
MC
Casa da AIDS, Division of Infectious and Parasitic Diseases, Hospital das Clinicas, Medical School, University of São Paulo, SP, Brazil. cassiamc@uol.com.br
Barone
Antonio Alci
AA
D000998:Antiviral Agents / Q000627:therapeutic use*; D001938:Brazil; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D012307:Risk Factors
D000998:Antiviral Agents